New protein-targeting drug shows promise in early trial for patients with high-risk CLL
A new oral targeted drug, idelalisib (GS-1101), has the potential to stave off the need for additional treatments for relapsed or treatment-resistant chronic lymphocytic leukemia (CLL), according to a study led in part by ...
Cancer
May 17, 2013 |
not rated yet |
0
|
Diverse genetic alterations found in triple-negative breast cancers after neoadjuvant chemotherapy
Many different genetic alterations were detected in tumor cells left behind after patients with triple-negative breast cancer were treated with chemotherapy prior to surgery (neoadjuvant chemotherapy), according to data presented ...
Cancer
Dec 07, 2012 |
not rated yet |
0
|
Enzyme offers new therapeutic target for cancer drugs
Researchers at the University of California, San Diego School of Medicine have uncovered a new signal transduction pathway specifically devoted to the regulation of alternative RNA splicing, a process that allows a single ...
Cancer
Jun 21, 2012 |
not rated yet |
0
|
Targeted agent addition to herceptin has positive effect on metastatic HER-2 breast cancer
Adding Afinitor to Herceptin, the main treatment for HER2-positive metastatic breast cancer, helps some women with disease that has been resistant to previous Herceptin-based therapies, according to a study led by researchers ...
Cancer
Jul 08, 2011 |
not rated yet |
0
|
Common genetic alteration found in head and neck cancers may not be key to effective treatment
Although a large majority of head and neck cancers have a deregulation of the PI3K/AKT/mTOR pathway, data recently published in Cancer Research, a journal of the American Association for Cancer Research, indicated that d ...
Cancer
Jan 29, 2013 |
not rated yet |
0
Early changes in liver function could detect life-threatening infection
Early changes in liver function detected by novel techniques can identify severe infection (sepsis) hours after onset and so could have important implications for the treatment of patients who are critically ill, according ...
Medical research
Nov 13, 2012 |
not rated yet |
0
Hedgehog pathway key in tamoxifen-resistant breast CA
(HealthDay)—Noncanonical Hedgehog (Hh) signaling is activated in tamoxifen-resistant tumors, and the phosphoinositide 3-kinase inhibitor/protein kinase B (PI3K/AKT) pathway plays a key role protecting Hh ...
Cancer
Nov 06, 2012 |
not rated yet |
0
Therapy exploits 'addiction' of leukemia cells
A new study describes a therapeutic approach to halting cancer progression by exploiting a previously unrecognized "addiction" of leukemia cells to specific signaling molecules. The research, published by Cell Press online ...
Cancer
Apr 16, 2012 |
not rated yet |
0
PI3K/mTOR pathway proteins tied to poor prognosis in breast cancer
Four proteins involved in translation, the final step of general protein production, are associated with poor prognosis in hormone-receptor-positive breast cancer when they are dysregulated, researchers reported at the AACR ...
Cancer
Apr 01, 2012 |
not rated yet |
0
Metastatic breast cancer hitches a free ride from the immune system
Inflammatory breast cancer (IBC) is the most lethal form of breast cancer . It spreads easily through the lymphatic and blood vessels, forming metastasis which can lead to multi-organ failure. New research published in BioMed ...
Immunology
Feb 10, 2012 |
not rated yet |
0
New breast cancer model of mutant PI3K recapitulates features of human breast cancer
Scientists from the Friedrich Miescher Institute for Biomedical Research have shown that a mutation in the lipid kinase PI3K, which occurs in about 30% of human breast cancers, itself evokes different forms ...
Cancer
Jul 12, 2011 |
not rated yet |
0
More than just a backup system: PI3K-Delta in tumour surveillance
If something is really important, it's best not to rely on it. This basic principle is followed equally by human engineers – for example, the NASA space shuttle has three main engines – and by nature. Thus it could ...
Cancer
Jan 30, 2013 |
not rated yet |
0
Patients with aberrations in two genes respond better to drugs blocking a well-known cancer pathway
Cancer patients with mutations or variations in two genes -– PIK3CA and PTEN -– who have failed to respond to several, standard treatments, respond significantly better to anti-cancer drugs that inhibit these genes' pathways ...
Cancer
Nov 07, 2012 |
not rated yet |
0
